Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug

Japanese Journal of Clinical Oncology

Volumn 36, Issue 4, 2006, Pages 207-211

  Inoh, Kazuhiko ^a   Muramatsu, Hisako ^a   Torii, Shuhei ^a   Ikematsu, Shinya ^b   Oda, Munehiro ^b   Kumai, Hideshi ^b   Sakuma, Sadatoshi ^c   Inui, Tatsuya ^d   Kimura, Terutoshi ^d   Muramatsu, Takashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEIJI DAIRIES CORPORATION   (Japan)

^c Cell Signals Inc   (Japan)

^d Peptide Institute Inc   (Japan)

Author keywords

Antibody; Cancer; Growth substances; Immunotoxins; Monoclonal

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; IMMUNOGLOBULIN G; MIDKINE; MIDKINE ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING SITE; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG CONJUGATION; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; PROTEIN DEFICIENCY; PROTEIN DOMAIN; PROTEIN SECRETION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; CYTOKINES; DOXORUBICIN; HUMANS; IMMUNOTOXINS; LIVER NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33745700682     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl004     Document Type: Article

References (42)

1. Aaronson SA. Growth factors and cancer. Science 1991;254:1146-53.
2. Muramatsu T. Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 2002;132:359-71.
3. Muramatsu T. Midkine. In: Wiley Encyclopedia of Molecular Medicine. John Wiley & Sons 2002; 2086-8.
4. Kadomatsu K, Tomomura M, Muramatsu, T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151:1312-8.
5. Merenmies J, Rauvala H. Molecular cloning of the 18-kDa growth-associated protein of developing brain. J Biol Chem 1990;265:16721-4.
6. Li YS, Milner PG, Chauhan AK, Watson MA, Hoffman RM, Kodner CM, et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science 1990;250:1690-4.
7. Muramatsu H, Muramatsu T. Purification of recombinant midkine and examination of its biological activities: Functional comparison of new heparin binding factors. Biochem Biophys Res Commun 1991;177:652-8.
8. Michikawa M, Kikuchi S, Muramatsu H, Muramatsu T, Kim SU. Retinoic acid responsive gene product, midkine (MK), has neurotrophic functions for mouse spinal cord and dorsal root ganglion neurons in culture. J Neurosc Res 1993;35:530-9.
9. Takada T, Toriyama K, Muramatsu H, Song XJ, Torii S, Muramatsu T. Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: Chemotactic activity to neutrophils and association with inflammatory synovitis. J Biochem 1997;122:453-8.
10. Horiba M, Kadomatsu K, Nakamura E, Muramatsu H, Ikematsu S, Sakuma S, et al. Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest 2000;105:489-95.
11. Sato W, Kadomatsu K, Yuzawa Y, Muramatsu H, Hotta N, Matsuo S, et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol 2001;167:3463-9.
12. Kojima S, Muramatsu H, Amanuma H, Muramatsu T. Midkine enhances fibrinolytic activity of bovine endothelial cells. J Biol Chem 1995;270:9590-6.
13. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997;57:1814-9.
14. Sumi Y, Muramatsu H, Takei Y, Hata K, Ueda M, Muramatsu T. Midkine, a heparin-binding growth factor promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model. J Cell Sci 2002;115:2659-67.
15. Tsutsui J, Kadomatsu K, Matsubara S, Nakagawara A, Hamanoue M, Takao S, et al. A new family of heparin-binding growth differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 1993;53:1281-5.
16. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 1995;55:1792-7.
17. Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, et al. Increased midkine gene expression in human gastrointestinal cancers. Jap J Cancer Res 1995;86:655-61.
18. Garver RI Jr, Chan CS, Milner P. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol 1993;9:463-6.
19. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994;74:1584-90.
20. Kato M, Maeta H, Kato S, Shinozawa T, Terada T. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod Pathol 2000;13:1060-5.
21. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999;57:253-7.
22. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996;56:2515-8.
23. Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, et al. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 1997;233:29-32.
24. Muramatsu H, Shirahama H, Yonezawa S, Maruta H, et al. Midkine (MK), a retinoic acid-inducible growth/differentiation factor: Immunochemical evidence for the function and distribution. Dev Biol 1993;159:392-402.
25. Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, et al. Antisense oligodeoxynucleotide targeted to midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001;61:8486-91.
26. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-41.
27. Shouval D, Adler R, Wands JR, Hurwitz E, Isselbacher KJ, Sela M. Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens. Proc Natl Acad Sci USA 1998;85:8276-80.
28. Sivam GP, Martin PJ, Reisfeld RA, Mueller BM. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma. Cancer Res 1995;55:2352-6.
29. Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Seleh M, Isaacs, C, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999;17:478-84.
30. Trail PA, Willner D, Lasch SJ, Henderson AJ, Greenfield RS, King D, et al. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 1992;52:5693-700.
31. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993;261:212-5.
32. Galfre G, Mestein C. Preparation of monoclonal antibodies: Strategies and procedures. Methods Enzymol 1981;73:3-46.
33. Nakamura E, Kadomatsu K, Yuasa S, Muramatsu H, Mamiya T, Nabeshima T, et al. Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Genes Cells 1998;3:811-22.
34. Willner D, Trail PA, Hofstead SJ, King HD, Lasch S J, Braslawsky GR, et al. (6-Maleimidocaproyl)hydrazone of doxorubicin - a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 1993;4:521-7.
35. Riddles PW, Blakeley RL, Zerner B. Ellman's reagent: 5,5′-dithiobis (2-nitrobenzoic acid)-a reexamination. Anal Biochem 1979;94:5-81.
36. Inui T, Bodi J, Kubo S, Nishio H, Kimura T, Kojima S, et al. Solution synthesis of human midkine, a novel heparin binding neurotrophic factor consisting of 121 amino acid residues with five disulphide bonds. J Peptide Science 1996;2:28-39.
37. Inui T, Makao M, Nishio H, Nishiuchi, Kojima S, Muramatsu T, et al. Solution synthesis and biological activity of human pleiotrophin, a novel heparin-binding neurotrophic factor consisting of 136 amino acid residues with five disulfide bonds. J Peptide Res 2000;55:384-97.
38. Shibata Y, Muramatsu T, Hirai M, Inui T, Kimura T, Saito H, et al. Nuclear targeting by the growth factor midkine. Mol Cell Biol 2002;22:6788-96.
39. Muramatsu H, Inui T, Kimura T, Sakakibara S, Song X, Maruta H, et al. Localization of heparin-binding, neurite outgrowth and antigenic regions in midkine molecule. Biochem Biophys Res Commun 1994;203:1131-9.
40. Muramatsu H, Zou K, Sakaguchi N, Ikematsu S, Sakuma S, Muramatsu T. LDL-receptor related protein as a component of the midkine receptor. Biochem Biophys Res Commun 2000;270:936-41.
41. Salama RHM, Muramatsu H, Zou K, Inui T, Kimura T, Muramatsu T. Midkine binds to 37-kDa laminin binding protein precursor, leading to nuclear transport of the complex. Exp Cell Res 2001;270:13-20.
42. Herz J, Beck HH. Lipoprotein receptors in the nervous system. Ann Rev Biochem 2002;71:405-34.